MedTrace Logo

Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer

NCT06984562 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2025-10-29

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if Adaptive Radiation Therapy (ART) is safe and effective in treating patients with locally advanced pancreatic cancer.

The main questions the study aims to answer are:

* Can ART improve how well radiation therapy targets the most aggressive cancer cells, while protecting the healthy tissue around the tumor?
* Can ART help reduce the side effects that participants may experience during treatment?

Participants will:

* Undergo CT scans to plan the exact location of the radiation treatment. During this process, 1-3 small markers may be placed in or near the tumor to help with the planning.
* Have a tumor biopsy, which involves taking a small sample of tissue from the cancer.
* Receive 5 radiation treatments every other day over a 2-week period.
* Provide blood samples before, during, and after your radiation treatment.

Conditions

  • Locally Advanced Pancreatic Ductal Adenocarcinoma (PDA)

Interventions

RADIATION

Adaptive Radiation Therapy

Adaptive Radiation Therapy (ART) creates a personalized radiation plan for each treatment session. This means the plan can change from day to day to more precisely target the tumor while protecting the surrounding healthy tissue. By closely shaping the radiation to match the tumor's location, ART may reduce the amount of radiation reaching nearby normal tissues. This can allow for higher, more focused doses of radiation to the tumor itself, which may help improve treatment effectiveness while reducing side effects.

Sponsors & Collaborators

  • Fox Chase Cancer Center

    lead OTHER

Principal Investigators

  • Joshua Meyer, MD · Fox Chase Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-20
Primary Completion
2028-08-01
Completion
2029-08-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06984562 on ClinicalTrials.gov